Stelic Institute & Co..

tin1.jpg

- Stelic Institute & Co., Inc. (“Stelic”) is a privately-held biotech company based in Tokyo, with a focus on the development of innovative therapies for fibrosis and cancer.

- STNM01 is a first-in-class molecule [synthetic oligonucleotide] that inhibits terminal glycosaminoglycan (GAG) sulfation of chondroitin sulfate chain.

  • - Stelic has completed a Phase 2a study in Germany for the treatment of non-healing mucosal lesion in drug-refractory, moderate to severe Ulcerative Colitis (UC) patients, with single-dosing of STNM01.
  • - An Investigator Initiated Trial (IIT) was also completed in Japan for biologics-refractory, acute exacerbation on chronic active UC patients with multiple-dosing regimen.
  • - In a Phase 1 study in Japan for refractory Crohn’s Disease (CD) patients, approximately 80% of patients showed quick mucosal healing (MH) response with histological repression of fibrosis (Suzuki K et al. DDW2014).
  • - In a multiple-dosing IIT study was also completed in Japan for biologics-refractory CD patients with severe large ulceration.

- Academic collaborators conducted studies with orally active formulation in mice. The prototype of orally active dsRNA oligonucleotide showed effective CHST15 silencing in not only colon but also small intestine in mice (Arumugan S et al. DDW2016 Lecture presentation).
- Another IIT was conducted in Japan for the treatment of drug-resistant, unresectable pancreatic cancer patients and STNM01 demonstrated excellent results (Nishimura M et al. DDW2016, DDW2015, ASCO2015, UEGW2015 Poster of excellence).


ページの先頭へ